• Tue. Oct 27th, 2020



Illumina in Talks to Buy Grail, Possibly for Over $8 Billion

Illumina  (ILMN) – Get Report shares fell Wednesday after a news report said the genetic-sequencing titan is discussing a deal to buy cancer-discovery startup Grail that might top $8 billion.

Illumina recently traded at $325.93, down 7.5%. The shares have eased 1% year to date.

Bloomberg secured the information from knowledgeable sources. Grail’s investors include Microsoft’s  (MSFT) – Get Report Bill Gates, Amazon’s  (AMZN) – Get Report Jeff Bezos, Merck  (MRK) – Get Report and Johnson & Johnson  (JNJ) – Get Report.

Source Article